Choices of stimulation for low responders in IVF

References

• Muasher SJ, Oehninger S, Simonetti S et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil. Steril.50, 298–307 (1988).
   PubMed Web of Science ®Google Scholar
• Galey-Fontaine J, Cedrin-Durnerin I, Chaibi R, Massin N, Hugues JN. Age and ovarian reserve are distinct predictive factors of cycle outcome in low responders. Reprod. Biomed. Online10, 94–99 (2005).
   PubMed Web of Science ®Google Scholar
• Hugues NJ, Cedrin Durnerin IC. Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum. Reprod. Update4, 83–101 (1998).
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update12, 685–718 (2006).
   PubMed Web of Science ®Google Scholar
• Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod. Biol. Endocrinol.5, 9 (2007).
   PubMed Web of Science ®Google Scholar
• Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ. Ultrasonography as a tool for the predicition of outcome in IVF patients: acomperative meta-analysis of ovarian volume and antral follicle count. Fertil. Steril.87, 764–775 (2007).
   PubMed Web of Science ®Google Scholar
• Broer SL, Mol BW, Hendriks D, Broekmans FK. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil. Steril. PMID: 18321493 (2008) (Epub ahead of print).
   Google Scholar
• Verhagen TE, Hendriks DJ, Bancsi LF, Mol BW, Broekmans FJ. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Hum. Reprod. Update14, 95–100 (2008).
   PubMed Web of Science ®Google Scholar
• Hofmann GE, Toner JP, Muasher SJ, Jones GS. High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization. J. in vitro Fert. Embryo Transf.6, 285–289 (1989).
   PubMedGoogle Scholar
• Karande VC, Jones GS, Veeck LL, Muasher SJ. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil. Steril.53, 486–489 (1990).
   PubMed Web of Science ®Google Scholar
• Van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum. Reprod.8, 369–373 (1993).
   PubMed Web of Science ®Google Scholar
• Land JA, Yarmolinskaya MI, Dumoulin JC, Evers JL. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil. Steril.65, 961–965 (1996).
   PubMed Web of Science ®Google Scholar
• Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotropins in IVF treatment:a randomized controlled trial. Hum. Reprod.20, 611–615 (2005).
   PubMed Web of Science ®Google Scholar
• Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsboll S, Nielsen IK, Andersen AN. A prospective randomized clinical trial comparing an individualdose of recombinant FSH based on predictive factors versus a ‘standard’dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment. Hum. Reprod.18, 2275–2282 (2003).
   PubMed Web of Science ®Google Scholar
• Rombauts L, Suikkari AM, MacLachlan V, Trounson AO, Healy DL. Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle. Fertil. Steril.69, 665–669 (1998).
   PubMed Web of Science ®Google Scholar
• Ibrahim ZH, Matson PL, Buck P, Lieberman BA. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate/human menopausal gonadotropin in women with a poor ovarian response. Fertil. Steril.55, 202–204 (1991).
   PubMed Web of Science ®Google Scholar
• Volpe A, Coukos G, Barreca A, Giordano G, Artini PG, Genazzani AR. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum. Reprod.6, 1228–1232 (1991).
   PubMed Web of Science ®Google Scholar
• Owen EJ, Sholam Z, Mason BA, Ostergaard H, Jacobs HS. Cotreatmentwith growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial. Fertil. Steril.56, 1104–1110 (1991).
   PubMed Web of Science ®Google Scholar
• Younis JS, Simon A, Koren R, Dorembus D, Schenker JG, Laufer N. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study. Fertil. Steril.58, 575–580 (1992).
   PubMed Web of Science ®Google Scholar
• Levron J, Lewit N, Erlik Y, Itskovitz-Eldor J. No beneficial effects of human growth hormone therapy in normal ovulatory patients with a poor ovarian response to gonadotropins. Gynecol. Obstet. Invest.35, 65–68 (1993).
   PubMed Web of Science ®Google Scholar
• Howles CM, Loumaye E, Germond M et al. Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization? Hum. Reprod.14, 1939–1943 (1999).
   PubMed Web of Science ®Google Scholar
• Kotarba D, Kotarba J, Hughes E. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev.2, CD000099 (2000).
   Google Scholar
• Harper K, Proctor M, Hughes E. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev.3, CD000099 (2003).
   Google Scholar
• Tesarik J, Hazout A, Mendoza C. Improvement of delivery and live birth rates after ICSI in women aged > 40 years by ovarian co-stimulation with growth hormone. Hum. Reprod.20, 2536–2541 (2005).
   PubMed Web of Science ®Google Scholar
• Feldberg D, Farhi J, Ashkenazi J, Dicker D, Shalev J, Ben Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil. Steril.62, 343–346 (1994).
   PubMed Web of Science ®Google Scholar
• Olivennes F, Righini C, Fanchin Ret al. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patientswith high follicle-stimulating hormone concentrations on day 3. Hum. Reprod.11, 1169–1172 (1996).
   PubMed Web of Science ®Google Scholar
• Faber B, Mayer J, Cox B et al. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil. Steril.69, 826–830 (1998).
   PubMed Web of Science ®Google Scholar
• Dirnfeld M, Fruchter O, Yshai D, Lissak A, Ahdut A, Abramovici H. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization. Fertil. Steril.72, 406–411 (1999).
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco JA, Isaza V, Requena A et al. High doses of gonadotropins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. Hum. Reprod.15, 2292–2296 (2000).
   PubMed Web of Science ®Google Scholar
• Schachter M, Friedler S, Raziel A, Strassburger D, Bern O, Ron-el R. Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase – a function of improved embryo quality. J. Assist. Reprod. Genet.18, 197–204 (2001).
   PubMed Web of Science ®Google Scholar
• Scott RT, Navot D. Enhancement ofovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil. Steril.61, 880–885 (1994).
   PubMed Web of Science ®Google Scholar
• Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil. Steril.67, 93–97 (1997).
   PubMed Web of Science ®Google Scholar
• Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil. Steril.69, 419–424 (1998).
   PubMed Web of Science ®Google Scholar
• Leondires MP, Escalpes M, Segars JH, Scott RT Jr, Miller BT. Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. Fertil. Steril.72, 1018–1023 (1999).
   PubMed Web of Science ®Google Scholar
• Confino E, Zhang X, Kazer RR. GnRHa flare and IVF pregnancy rates. Int. J. Gynaecol. Obstet.85, 36–39 (2004).
   PubMed Web of Science ®Google Scholar
• Detti L, Williams DB, Robins JC, Maxwell RA, Thomas MA. A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization. Fertil. Steril.84, 1401–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Weissman A, Farhi J, Royburt M, Nahum H, Glezerman M, Levran D. Prospective evaluation of two stimulation protocols for low responders who were undergoing in vitro fertilization-embryo transfer. Fertil. Steril.79, 886–892 (2003).
   PubMed Web of Science ®Google Scholar
• Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols. Hum. Reprod.14, 2959–2962 (1999).
   PubMed Web of Science ®Google Scholar
• Nikolettos N, Al-Hasani S, Felberbaum R et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur. J. Obstet. Gynecol. Reprod. Biol.97, 202–207 (2001).
   PubMed Web of Science ®Google Scholar
• Cheung LP, Lam PM, Lok IH et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomised controlled trial. Hum. Reprod.20, 616–621 (2005).
   PubMed Web of Science ®Google Scholar
• Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum. Reprod.16, 868–870 (2001).
   PubMed Web of Science ®Google Scholar
• Mohamed KA, Davies WA, Allsopp J, Lashen H. Agonist “flare-up” versus antagonist in the management of poor responders undergoing in vitro fertilization treatment. Fertil. Steril.83, 331–335 (2005).
   PubMed Web of Science ®Google Scholar
• Malmusi S, La Marca A, Giulini S et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil. Steril.84, 402–406 (2005).
   PubMed Web of Science ®Google Scholar
• D’Amato G, Caroppo E, Pasquadibisceglie A, Carone D, Vitti A, Vizziello GM. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertil. Steril.81, 1572–1577 (2004).
   PubMed Web of Science ®Google Scholar
• Weghofer A, Margreiter M, Bassim S, Sevelda U, Beilhack E, Feichtinger W. Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertil. Steril.81, 1002–1006 (2004).
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil. Steril.77, 776–780 (2002).
   PubMed Web of Science ®Google Scholar
• Schoolcraft WB, Surrey ES, Minjarez DA, Stevens JM, Gardner DK. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? Fertil. Steril.89, 151–156 (2008).
   PubMed Web of Science ®Google Scholar
• Bassil S, Godin PA, Donnez J. Outcome of in-vitro fertilization through natural cycles in poor responders. Hum. Reprod.14, 1262–1265 (1999).
   PubMed Web of Science ®Google Scholar
• Morgia F, Sbracia M, Schimberni M et al. A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization. Fertil. Steril.81, 1542–1547 (2004).
   PubMed Web of Science ®Google Scholar